Weihong He

Dr. Weihong He

Department of Physiology, Sichuan University, Chengdu, Sichuan, China
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2018 in Circulation
Verified
Journal Article
Open access
PDF file
CMCharlotte S. McCarroll
Charlotte S. McCarroll
Weihong HeWeihong He
Weihong He
KFKirsty Foote
Kirsty Foote
ABAshley Bradley
Ashley Bradley
KMKaren Mcglynn
Karen Mcglynn
CLChristopher M. Loughrey
Christopher M. Loughrey
Background: Myocardial infarction (MI) is a leading cause of heart failure and death worldwide. Preservation of contractile function and protection against adverse changes in ventricular architecture (cardiac remodeling) are key factors to limiting progression of this condition to heart failure. Consequently, new therapeutic targets are urgently required to achieve this aim. Expression of the Runx1 transcription factor is increased in adult cardiomyocytes after MI; however, the functional role of Runx1 in the heart is unknown. Methods: To address this question, we have generated a novel tamoxifen-inducible cardiomyocyte-specific Runx1 -deficient mouse. Mice were subjected to MI by means of coronary artery ligation. Cardiac remodeling and contractile function were assessed extensively at the whole-heart, cardiomyocyte, and molecular levels. Results: Runx1 -deficient mice were protected against adverse cardiac remodeling after MI, maintaining ventricular wall thickness and contractile function. Furthermore, these mice lacked eccentric hypertrophy, and their cardiomyocytes exhibited markedly improved calcium handling. At the mechanistic level, these effects were achieved through increased phosphorylation of phospholamban by protein kinase A and relief of sarco/endoplasmic reticulum Ca 2+ -ATPase inhibition. Enhanced sarco/endoplasmic reticulum Ca 2+ -ATPase activity in Runx1-deficient mice increased sarcoplasmic reticulum calcium content and sarcoplasmic reticulum–mediated calcium release, preserving cardiomyocyte contraction after MI. Conclusions: Our data identified Runx1 as a novel therapeutic target with translational potential to counteract the effects of adverse cardiac remodeling, thereby improving survival and quality of life among patients with MI.


5 June 2009 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LYLiping Yang
Liping Yang
PCPing Cheng
Ping Cheng
XPXing-Chen Peng
Xing-Chen Peng
HSHua-Shan Shi
Hua-Shan Shi
Weihong HeWeihong He
Weihong He
LYLi Yang
Li Yang
Angiogenesis plays an important role in tumor growth, invasion, and eventually metastasis. Antiangiogenic strategies have been proven to be a promising approach for clinical therapy for a variety of tumors. As a potent inhibitor of tumor angiogenesis, pigment epithelium-derived factor (PEDF) has recently been studied and used as an anticancer agent in several tumor models.

7 September 2021 in BMC Neurology
Verified
Journal Article
Open access
PDF file
YWYanan Wang
Yanan Wang
HHHexiao Huang
Hexiao Huang
Weihong HeWeihong He
Weihong He
SZShihong Zhang
Shihong Zhang
MLMing Liu
Ming Liu
SWSimiao Wu
Simiao Wu
Background: We aimed to explore the association of serum level of the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) and its related inflammatory biomarkers (hypoxia inducible factor-1α, cathepsin B, caspase-1 and matrix metalloproteinase-9) with malignant brain edema (MBE) in patients with acute ischemic stroke. Methods: We prospectively enrolled patients with acute ischemic stroke admitted < 24 h from onset of symptoms. Brain CT was performed on admission and blood samples were collected. Repeated brain CT/MRI was performed < 7 days of admission to identify the presence of MBE, defined as neurological deterioration with imaging signs of midline shift or compressed basal cisterns. Logistic regression analysis was performed to assess the association between inflammatory biomarkers and MBE, adjusted for age and National Institutes of Health Stroke Scale (NIHSS). Results: 200 patients (69.3 ± 14.3 years; male 55 %) were included for analysis, of whom 26 patients developed MBE (median time from stroke onset to MBE 32.5 h). Compared with patients without MBE, those with MBE had higher level of serum concentration of NLRP3 (median time from onset to blood collection 3 h, 1.85 ng/ml vs. 1.11 ng/ml, P = 0.026). NLRP3 level was positively correlated with NIHSS on admission (Spearman ρ = 0.18, P = 0.01) and the association between NLRP3 and MBE was attenuated (OR 1.47, 95 % CI 0.88–2.46, P = 0.138) after adjusting for age and NIHSS. There was no significant difference in other biomarkers between MBE and non-MBE groups. Conclusions: There was a trend of association between a higher level of serum concentration of NLRP3 and an increased risk of MBE after ischemic stroke, possibly confounded by the severity of stroke, which is worth further validation in large cohort studies.

16 June 2021 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
Weihong HeWeihong He
Weihong He
CMCharlotte S McCarroll
Charlotte S McCarroll
KNKatrin Nather
Katrin Nather
KFKristopher Ford
Kristopher Ford
KMKenneth Mangion
Kenneth Mangion
CLChristopher M Loughrey
Christopher M Loughrey
Identifying novel mediators of lethal myocardial reperfusion injury that can be targeted during primary percutaneous coronary intervention (PPCI) is key to limiting the progression of patients with ST-elevation myocardial infarction (STEMI) to heart failure. Here, we show through parallel clinical and integrative preclinical studies the significance of the protease cathepsin-L on cardiac function during reperfusion injury. We found that direct cardiac release of cathepsin-L in STEMI patients (n = 76) immediately post-PPCI leads to elevated serum cathepsin-L levels and that serum levels of cathepsin-L in the first 24 h post-reperfusion are associated with reduced cardiac contractile function and increased infarct size. Preclinical studies demonstrate that inhibition of cathepsin-L release following reperfusion injury with CAA0225 reduces infarct size and improves cardiac contractile function by limiting abnormal cardiomyocyte calcium handling and apoptosis. Our findings suggest that cathepsin-L is a novel therapeutic target that could be exploited clinically to counteract the deleterious effects of acute reperfusion injury after an acute STEMI.

28 September 2024 in Matrix Biology
Verified
Journal Article
Closed access
XWXiaoli Wang
Xiaoli Wang
JRJie Ren
Jie Ren
FFFei Fang
Fei Fang
EWErxiang Wang
Erxiang Wang
JLJianwei Li
Jianwei Li
Xiao-heng LiuXiao-heng Liu
Xiao-heng Liu